Fresenius Medical Care AG

BRSE:FME Stock Report

Market Cap: CHF 12.0b

Fresenius Medical Care Valuation

Is FME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FME (CHF41.45) is trading below our estimate of fair value (CHF142.5)

Significantly Below Fair Value: FME is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FME?

Key metric: As FME is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for FME. This is calculated by dividing FME's market cap by their current earnings.
What is FME's PE Ratio?
PE Ratio19.5x
Earnings€658.94m
Market Cap€12.88b

Price to Earnings Ratio vs Peers

How does FME's PE Ratio compare to its peers?

The above table shows the PE ratio for FME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.4x
SOON Sonova Holding
30.9x11.4%CHF 17.5b
GALE Galenica
21.4x5.3%CHF 3.6b
STMN Straumann Holding
62.9x21.2%CHF 18.1b
YPSN Ypsomed Holding
66.3x41.1%CHF 4.9b
FME Fresenius Medical Care
19.5x19.3%CHF 12.9b

Price-To-Earnings vs Peers: FME is good value based on its Price-To-Earnings Ratio (19.5x) compared to the peer average (45.4x).

Price to Earnings Ratio vs Industry

How does FME's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
FME 19.5xIndustry Avg. 18.5xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: FME is expensive based on its Price-To-Earnings Ratio (19.5x) compared to the European Healthcare industry average (18.5x).

Price to Earnings Ratio vs Fair Ratio

What is FME's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FME PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate FME's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FME forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 41.45
CHF 38.74
-6.5%
17.4%CHF 56.18CHF 27.15n/a18
Dec ’25n/a
CHF 37.11
0%
18.5%CHF 55.76CHF 26.95n/a18
Nov ’25n/a
CHF 36.76
0%
18.5%CHF 56.06CHF 27.09n/a18
Oct ’25n/a
CHF 36.60
0%
20.1%CHF 56.53CHF 24.50n/a18
Sep ’25n/a
CHF 37.10
0%
20.1%CHF 57.38CHF 24.86n/a18
Aug ’25n/a
CHF 37.10
0%
19.6%CHF 57.02CHF 24.71n/a18
Jul ’25n/a
CHF 39.04
0%
18.2%CHF 57.13CHF 25.39n/a19
Jun ’25CHF 38.16
CHF 39.55
+3.6%
18.3%CHF 57.95CHF 25.76n/a19
May ’25CHF 36.89
CHF 38.33
+3.9%
18.5%CHF 57.25CHF 25.44n/a19
Apr ’25n/a
CHF 37.90
0%
19.2%CHF 56.91CHF 25.29n/a19
Mar ’25n/a
CHF 39.02
0%
25.8%CHF 69.77CHF 24.85n/a20
Feb ’25CHF 34.25
CHF 37.93
+10.7%
25.8%CHF 66.19CHF 22.38n/a20
Jan ’25n/a
CHF 39.72
0%
26.1%CHF 67.39CHF 22.78n/a19
Dec ’24CHF 35.82
CHF 39.93
+11.5%
26.0%CHF 67.66CHF 22.87n/a19
Nov ’24n/a
CHF 41.07
0%
21.6%CHF 57.04CHF 22.81n/a18
Oct ’24CHF 40.60
CHF 42.84
+5.5%
22.3%CHF 64.25CHF 23.02n/a18
Sep ’24n/a
CHF 42.59
0%
22.3%CHF 64.12CHF 22.97n/a19
Aug ’24n/a
CHF 39.24
0%
27.3%CHF 64.25CHF 20.14n/a18
Jul ’24n/a
CHF 37.27
0%
27.9%CHF 65.44CHF 20.51n/a17
Jun ’24n/a
CHF 36.02
0%
31.2%CHF 65.24CHF 16.94CHF 38.1617
May ’24n/a
CHF 35.36
0%
32.2%CHF 65.99CHF 17.14CHF 36.8916
Apr ’24n/a
CHF 33.41
0%
33.2%CHF 65.68CHF 17.06n/a16
Mar ’24n/a
CHF 33.27
0%
34.9%CHF 66.76CHF 17.34n/a15
Feb ’24n/a
CHF 32.63
0%
36.0%CHF 66.68CHF 17.02CHF 34.2515
Jan ’24n/a
CHF 33.65
0%
33.3%CHF 66.08CHF 16.86n/a15
Dec ’23n/a
CHF 33.76
0%
34.3%CHF 66.00CHF 16.84CHF 35.8214

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:13
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresenius Medical Care AG is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Brian WilliamsAvondale Partners
Olav ZilianBaader Helvea Equity Research